Efficacy and safety of insulin glulisine in patients with type 1 diabetes

Hormone and Metabolic Research

Volumn 37, Issue 11, 2005, Pages 702-707

  Dreyer, M ^a   Prager, R ^b   Robinson, A ^c   Busch, K ^d   Ellis, G ^e   Souhami, E ^e   Van Leendert, R ^f  

^a Krankenhaus Bethanien   (Germany)

^b UNIVERSITY OF VIENNA   (Austria)

^c ROYAL UNITED HOSPITAL   (United Kingdom)

^d University of Wales College of Medicine ^*

^e SANOFI   (France)

^f UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Diabetes mellitus; Glycaemic control; Rapid acting insulin analogues

Indexed keywords

GLULISINE; HEMOGLOBIN A1C; INSULIN; INSULIN GLULISINE; INSULIN LISPRO;

ADULT; ANTIBODY PRODUCTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIBODIES, BACTERIAL; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DRUG HYPERSENSITIVITY; ESCHERICHIA COLI; FEMALE; HUMANS; INSULIN; INSULIN ANTIBODIES; MALE; MIDDLE AGED;

EID: 29144461567     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-870584     Document Type: Article

References (9)

1. DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986
2. Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care 1998; 21: 1910-1914
3. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148
4. Becker R, Frick A, Wessels D, Scholtz HE. Evaluation of the pharmacodynamic and pharmacokinetic profiles of insulin glulisine - a novel, rapid-acting, human insulin analogue. Diabetologia 2003; 46: Abs 775
5. Frick A, Becker R, Wessels D, Scholtz HE. Pharmacokinetic and glucodynamic profiles of insulin glulisine: an evaluation following subcutaneous administration at various injection sites. Diabetologia 2003; 46: Abs 776
6. Lalli C, Ciofetta M, Del Sindaco P, Torlone E, Pampanelli S, Campagnucci P, Cartechini MG, Bartocci L, Brunetti P, Bolli GB. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 1999; 22: 468-477
7. Raskin P, Guthrie RA, Leiter L, Riss A, Jovanic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with Type 1 diabetes. Diabetes Care 2000; 23: 583-588
8. Kroon K. Chapter 13: Insulin - pharmacology, types of regimens and adjustments, www.endotext.com. Accessed in October 2003
9. Frick A, Burger F, Scholz H, Becker RHA. Time-action profile of insulin glulisine versus regular human insulin and insulin lispro in obese subjects. Diabetes 2004; 52 (Suppl 2): A124 (Abstract 526-P)